Test Price
2,800 AED✅ Home Collection Available
HR Gene Atrichia with Papular Lesions Genetic Test in UAE | 2800 AED | DHA Licensed Laboratory
Executive Summary & Core Metrics
The HR Gene Atrichia with Papular Lesions Genetic Test is a targeted diagnostic assay that detects pathogenic variants in the HR gene, the confirmed molecular cause of this rare autosomal recessive disorder. Using next‑generation sequencing (NGS) with 99.9% analytical sensitivity and Sanger confirmation, the test delivers definitive results for patients presenting with complete, irreversible hair loss and characteristic keratinous papules. Our DHA‑licensed facility (License 1143) in Dubai Healthcare City processes samples with a turnaround of 3–4 weeks, supported by physician‑interpreted reporting and post‑test genetic counseling. The assay is available through VIP mobile phlebotomy or FTA card collection, operating daily from 8 AM to 11 PM with full cold‑chain integrity.
Test Overview & Methodology
This molecular genetic test analyzes the coding regions and splice junctions of the HR gene using hybridization‑capture NGS chemistry, followed by bidirectional Sanger sequencing to confirm all clinically significant variants. The methodology achieves 99.9% sensitivity and 99.9% specificity for single‑nucleotide variants and small insertions/deletions within the target region. Biallelic loss‑of‑function mutations in HR disrupt hair follicle cycling, leading to the classic phenotype of congenital atrichia with papular lesions (APL). Results are interpreted by a Consultant Medical Geneticist and delivered in a comprehensive report that includes variant classification per ACMG guidelines, clinical correlation, and reproductive risk assessment.
| Feature | Our Test – HR Gene NGS | Alternative – Whole Exome Sequencing |
|---|---|---|
| Precision | Targeted HR gene + Sanger confirmation; 99.9% sensitivity | Broad exome coverage; frequent variants of uncertain significance |
| Methodology | Hybrid‑capture NGS + bidirectional Sanger sequencing | Exome NGS only |
| Turnaround | 3–4 weeks | 6–12 weeks |
| Cost in UAE | 2,800 AED | 4,500–6,000 AED |
| DHA License | Facility License 1143 | Variable |
Physician Insight & Safety Protocols
“The HR gene plays a critical role in hair follicle development and cycling. Biallelic pathogenic mutations in HR result in a distinct clinical syndrome of congenital atrichia with papular lesions. This targeted genetic test provides a definitive molecular diagnosis, which is essential for accurate genetic counseling, recurrence risk estimation for family planning, and eligibility assessment for emerging therapies. However, clinicians must correlate genetic results with thorough dermatological examination and family history, as phenotypic overlap with other ectodermal dysplasias exists.” — Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory Notice
This genetic test is a diagnostic tool and does not replace clinical examination or ongoing medical management. Patients should continue all prescribed treatments unless directed otherwise by their physician. Test results must be interpreted in the full context of clinical presentation, family history, and additional laboratory findings.
Safety & Exclusion Criteria
- Exclusion criteria: Patients with severe anemia, active infection, or bleeding disorders require clinical assessment before sample collection. Modified collection procedures may be necessary.
- Pediatric considerations: For minors, explicit guardian consent and a child‑safeguarding assessment are mandatory. Any suspicion of non‑accidental injury must be reported to UAE child protection authorities in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Test limitations: Only the HR gene is analyzed; other genes associated with hereditary hair loss or ectodermal dysplasias are not included. Results must be interpreted by a qualified clinical geneticist.
Patient FAQ & Clinical Guidance
1. What is the HR gene and how does it cause Atrichia with Papular Lesions?
The HR gene encodes a nuclear protein that regulates hair follicle cycling and keratinocyte differentiation. Biallelic loss‑of‑function mutations disrupt this cycle, resulting in irreversible, complete alopecia along with the development of keratinous papules on the skin surface. This test identifies those causative mutations with high precision.
2. How is the sample collected and can it be done at home?
Sample collection is available through our VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection service, operating daily from 8 AM to 11 PM. A trained phlebotomist will collect peripheral blood in EDTA tubes or obtain a finger‑prick FTA card. Alternatively, you may visit our DHA‑licensed laboratory in Dubai Healthcare City for in‑person collection.
3. What does a positive result mean for my family planning options?
A confirmed biallelic HR mutation indicates autosomal recessive inheritance. Each pregnancy of carrier parents has a 25% risk of being affected. Definitive diagnosis enables accurate recurrence risk counseling, carrier testing for relatives, and consideration of preimplantation genetic diagnosis (PGD) or prenatal diagnosis in future pregnancies.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates under DHA Facility License 1143 and complies fully with UAE federal data protection and health information governance frameworks. All genetic data is processed, stored, and transmitted in accordance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent, data minimization, and purpose limitation are enforced throughout the testing lifecycle. No genetic data is shared with third parties without explicit written authorization. Our laboratory infrastructure meets ISO 27001 standards for information security management.
Clinical & Logistical Metadata
| Test Name | HR Gene Atrichia with Papular Lesions Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Peripheral whole blood (EDTA), extracted DNA, or FTA card (finger‑prick) |
| Methodology Used | Hybrid‑capture next‑generation sequencing + bidirectional Sanger confirmation |
| ICD-10-CM Code | Q84.0, L63.8 |
| LOINC Code | 21636-6 |
| DHA Facility License & Address | License 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians